Evidence map›Paper›PMID 31327392›Full record

ReviewAlzheimer's & dementia : the journal of the Alzheimer's Association2019

Preventing dementia by preventing stroke: The Berlin Manifesto.

Vladimir Hachinski, Karl Einhäupl, Detlev Ganten, Suvarna Alladi, Carol Brayne, Blossom C M Stephan, Melanie D Sweeney, Berislav Zlokovic, Yasser Iturria-Medina, Costantino Iadecola and 16 more

2 registry-linked trialsOpen access · goldAbstract readReview
In one paragraph

Review in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 159 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
159citing papers in PubMed, 14 pooled it
19.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06734286 narecruitingnot on this mapstarted 2024, after this paper: background citation

CogMed Intervention Targeting Working Memory in Patients with Mild Cognitive Impairment

TypeinterventionalSponsorSt. Joseph's Hospital and Medical Center, PhoenixRan2024 to 2025Enrolled10ConditionsMild Cognitive Impairment (MCI)ArmsCogMed
NCT07592962 recruitingnot on this mapstarted 2026, after this paper: background citation

Whole-life Investigation of Lishui Longevity Cohort Study

Typeobservational_patient_registrySponsorThe Fifth Affiliated Hospital of Wenzhou Medical University & Lishui Central HospitalRan2026 to 2036Enrolled4,500ConditionsIschemic Stroke, Chronic Disease, Cardiovascular
3 · Its place in the literature

Who cites it

159 citing papers in PubMed, 14 syntheses or guidelines pooled it, 325 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Cognitive impairment in sporadic cerebral small vessel disease: A systematic review and meta-analysis.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2021
    Pooled it
  12. Pooled it
  13. Pooled it
  14. Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2020
    Guideline
  15. Trial
  16. Trial
  17. Article
  18. Article
  19. Article
  20. Article

99 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors at 20 institutions in 7 countries.

Vladimir HachinskiDepartment of Clinical Neurological Sciences, Western University, Ontario, Canada. Electronic address: Vladimir.hachinski@lhsc.on.ca.
Karl EinhäuplDepartment of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Detlev GantenCharité - Universitätsmedizin Berlin, Berlin, Germany.
Suvarna AlladiDepartment of Neurology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India.
Carol BrayneDepartment of Public Health and Primary Care in the University of Cambridge, Cambridge, UK.
Blossom C M StephanInstitute of Mental Health, Division of Psychiatry and Applied Psychology, School of Medicine, University of Nottingham, Nottingham, UK.
Melanie D SweeneyDepartment of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Berislav ZlokovicDepartment of Physiology and Neuroscience, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Yasser Iturria-MedinaDepartment of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada.
Costantino IadecolaFeil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.
Nozomi NishimuraMeinig School of Biomedical Engineering, Cornell University, Ithaca, NY, USA.
Chris B SchafferMeinig School of Biomedical Engineering, Cornell University, Ithaca, NY, USA.
Shawn N WhiteheadDepartment of Anatomy and Cell Biology, Western University, Ontario, Canada.
Sandra E BlackDepartment of Medicine (Neurology), Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.
Leif ØstergaardDepartment of Clinical Medicine, Center of Functionally Integrative Neuroscience, Aarhus University, Aarhus, Denmark; Department of Neuroradiology, Aarhus University Hospital, Aarhus, Denmark.
Joanna WardlawCentre for Clinical Brain Sciences, Edinburgh Imaging, UK Dementia Research Institute, University of Edinburgh, Scotland, UK.
Steven GreenbergDepartment of Neurology, Massachusetts General Hospital, Boston, MA, USA.
Leif FribergDepartment of Clinical Sciences, Karolinska Institute, Stockholm, Sweden.
Bo NorrvingDepartment of Clinical Sciences, Neurology, Lund University, Lund, Sweden.
Brian RoweDepartment of Emergency Medicine and School of Public Health, University of Alberta, Edmonton, Alberta, Canada.
Yves JoanetteCanadian Institute of Health and Research, Ottawa, Canada.
Werner HackeDepartment of Neurology, Heidelberg University, Heidelberg, Germany.
Lewis KullerDepartment of Epidemiology, University of Pittsburgh, Pittsburgh, PA, USA.
Martin DichgansInstitute for Stroke and Dementia Research (ISD), University Hospital, Ludwig-Maximilians-Universität LMU, Munich, Germany; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany; German Center for Neurodegenerative Diseases (DZNE, Munich), Munich, Germany.
Matthias EndresDepartment of Neurology with Experimental Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Center for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Berlin, Germany; ExcellenceCluster NeuroCure, Charité-Universitätsmedizin Berlin, Berlin, Germany; German Center for Neurodegenerative Diseases (DZNE), partner site Berlin, Berlin, Germany; German Centre for Cardiovascular Research (DZHK), partner site Berlin, Berlin, Germany; Berlin Institute of Health (BIH), Berlin, Germany.
Zaven S KhachaturianPrevent Alzheimer Disease (PAD2020), Potamac, MD, USA.
Charité - Universitätsmedizin Berlin · DECornell University · USUniversity of Southern California · USWestern University · CAAarhus University · DKCanadian Institute of Child Health · CAGerman Centre for Cardiovascular Research · DEHeidelberg University · DEInstitute of Mental Health · GBKarolinska Institutet · SELudwig-Maximilians-Universität München · DELund University · SEMassachusetts General Hospital · USMcGill University · CANational Institute of Mental Health and Neurosciences · INPrevent Alzheimer’s Disease 2020 · USSunnybrook Health Science Centre · CAUniversity of Alberta · CAUniversity of Cambridge · GBUniversity of Edinburgh · GB

Funding

VASCULAR RISK AND COGNITIVE STATUS IN A LATINO POPULATIONP50AG005142 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI CHUI, HELENA CHANG · 1985 to 2019
$41.0M
Vascular Contributions to Dementia and Genetic Risk Factors for Alzheimer's DiseaseP01AG052350 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Daniel A Nation, ARTHUR W TOGA · 2016 to 2026
$28.4M
Overexpression of the amyloid precursor protein and cerebrovascular regulationR01NS037853 · NINDS · WEILL MEDICAL COLL OF CORNELL UNIV · PI Costantino Iadecola · 1998 to 2026
$10.6M
NO SYNTHASE GENE EXPRESSION AND CEREBRAL ISCHEMIC DAMAGER01NS034179 · NINDS · WEILL MEDICAL COLL OF CORNELL UNIV · PI IADECOLA, COSTANTINO · 1995 to 2021
$5.5M
ApoE4 and mechanisms of diffuse white matter injuryR01NS100447 · NINDS · WEILL MEDICAL COLL OF CORNELL UNIV · PI IADECOLA, COSTANTINO · 2016 to 2020
$3.5M
British Heart Foundation CS/15/5/31475Medical Research Council G0701120Medical Research Council G1001245Medical Research Council MR/J006971/1Medical Research Council MR/L023784/2NIA NIH HHS P01 AG052350NIA NIH HHS P50 AG005142NINDS NIH HHS R01 NS034179NINDS NIH HHS R01 NS037853NINDS NIH HHS R01 NS100447The Dunhill Medical Trust R380R/1114
6 · The paper itself

Abstract

The incidence of stroke and dementia are diverging across the world, rising for those in low- and middle-income countries and falling in those in high-income countries. This suggests that whatever factors cause these trends are potentially modifiable. At the population level, neurological disorders as a group account for the largest proportion of disability-adjusted life years globally (10%). Among neurological disorders, stroke (42%) and dementia (10%) dominate. Stroke and dementia confer risks for each other and share some of the same, largely modifiable, risk and protective factors. In principle, 90% of strokes and 35% of dementias have been estimated to be preventable. Because a stroke doubles the chance of developing dementia and stroke is more common than dementia, more than a third of dementias could be prevented by preventing stroke. Developments at the pathological, pathophysiological, and clinical level also point to new directions. Growing understanding of brain pathophysiology has unveiled the reciprocal interaction of cerebrovascular disease and neurodegeneration identifying new therapeutic targets to include protection of the endothelium, the blood-brain barrier, and other components of the neurovascular unit. In addition, targeting amyloid angiopathy aspects of inflammation and genetic manipulation hold new testable promise. In the meantime, accumulating evidence suggests that whole populations experiencing improved education, and lower vascular risk factor profiles (e.g., reduced prevalence of smoking) and vascular disease, including stroke, have better cognitive function and lower dementia rates. At the individual levels, trials have demonstrated that anticoagulation of atrial fibrillation can reduce the risk of dementia by 48% and that systolic blood pressure lower than 140 mmHg may be better for the brain. Based on these considerations, the World Stroke Organization has issued a proclamation, endorsed by all the major international organizations focused on global brain and cardiovascular health, calling for the joint prevention of stroke and dementia. This article summarizes the evidence for translation into action.

Indexed as

Atrial FibrillationBlood-Brain BarrierBrainCerebrovascular DisordersDementiaGlobal HealthHumansHypertensionIncidenceStrokeAlzheimer's diseaseCognitive impairmentDementiaNeurovascular unitPolicyPreventionResilienceRisk factor reductionStrokeTreatment

Identifiers

PMID31327392
PMCPMC7001744
OpenAlexW2958978007

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.